Response of a cell-surface NADH oxidase to the antitumor sulfonylurea N-(4-methylphenylsulfonyl)-N′-(4-chlorophenylurea) (LY181984) modulated by redox  by Morré, D.James et al.
 .Biochimica et Biophysica Acta 1369 1998 185–192
Response of a cell-surface NADH oxidase to the antitumor sulfonylurea
 / X  /  /N- 4-methylphenylsulfonyl -N - 4-chlorophenylurea LY181984
modulated by redox
D. James Morre a,), Lian-Ying Wu b, Dorothy M. Morre b´ ´
a Department of Medicinal Chemistry and Molecular Pharmacology, Purdue Uni˝ersity, West Lafayette, IN 47907, USA
b Department of Foods and Nutrition, Purdue Uni˝ersity, West Lafayette, IN 47907, USA
Received 8 July 1997; accepted 13 August 1997
Abstract
In previous reports, our laboratory has described a drug-responsive NADH oxidase activity of the external surface of the
plasma membrane of HeLa and other cancer cells, but not from normal cells, that was shed into media conditioned by the
growth of cancer cells such as HeLa and also into sera of cancer patients. The sulfonylurea-altered activity was found in
sera of a wide variety of cancer patients but the activity was either inhibited or stimulated by 1 mM LY181984. In this
report, we demonstrate that one basis for whether or not the activity was stimulated or inhibited may be the redox
 .environment of the protein. If plasma membrane vesicles from HeLa cells were first treated with dithiothreitol DTT or
 .with reduced glutathione GSH and then assayed for NADH oxidase activity, the sulfonylurea inhibited the activity in a
concentration-dependent manner. In contrast, if the plasma membrane vesicles were first treated with diluted hydrogen
 .peroxide or oxidized glutathione GSSG and then assayed for NADH oxidase activity, the antitumor sulfonylurea
stimulated the activity. Growth experiments were conducted in parallel. LY181984 administered to HeLa cells in the
presence of GSH was approximately 2 log orders more effective than LY181984 administered to HeLa cells in the presence
of GSSG. Similar results were found in the sera of cancer patients. With sera from normal individuals or with plasma
membranes of rat liver, the oxidizing or reducing conditions were without effect. The findings suggest that the response of
the cell surface NADH oxidase of HeLa cells to the antitumor sulfonylurea LY181984 is influenced by the redox
environment which may determine whether the drug will stimulate or inhibit the activity and that the degree of response
may be reflected in the ability of LY181984 to inhibit HeLa cell growth. q 1998 Elsevier Science B.V.
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1. Introduction
Plasma membrane vesicles of cultured HeLa S
cells bound the tritiated antitumor sulfonylurea
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w3 x .  . XH LY181984 N- 4-methylphenylsulfonyl -N -
 . 4-chlorophenylurea with high affinity K of ca.d
. w x30 nM 1 . Subsequently, a binding protein with one
or more thiols in an active site, was identified and
labeled with radioactive thiol reagents in sulfonylurea
protection experiments. Binding proteins of ca. 34 kD
w xM were labeled 2 .r
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The 34 kD sulfonylurea binding protein was
demonstrated to be correlated with an NADH oxidase
w xactivity 3 . The antitumor sulfonylurea LY181984
inhibited the oxidation of NADH by isolated vesicles
of plasma membranes from HeLa cells. Both right
side-out and inside-out vesicles of plasma membranes
from HeLa cells oxidized NADH but only the oxida-
tion of NADH with right side-out vesicles was inhib-
w xited by LY181984 4 . These findings suggested that
the oxidation of NADH by plasma membrane vesi-
cles from HeLa cells was inhibited by LY181984 at
w xan external site 4 . The LY181984-inhibited NADH
oxidase was subsequently shown to be released by
HeLa cells and to accumulate in culture media condi-
tioned by growth of HeLa cells. The shed form of the
activity was isolated from conditioned culture media
and shown to correlate with a ca. 33.5 kD protein on
w xSDS-PAGE 5 .
A shed form of the activity was found, as well, in
sera from tumor-bearing rats and from cancer patients
w x6 . The serum form showed the same drug specificity
as the plasma membrane-associated form and that
shed into culture media by HeLa cells. The NADH
oxidase was responsive to the antitumor sulfonylurea
 . X  .N- 4-methylphenylsulfonyl -N - 4-chlorophenylurea
 .LY181984 with sera from both tumor-bearing rats
and cancer patients. With sera from control rats,
normal volunteers or patients with disorders other
than cancer, the drug was without effect on the
NADH oxidase activity of the sera. With sera from
cancer patients, LY181984 added at a final concentra-
tion of 1 mM either inhibited or stimulated the activ-
ity. This was in contrast to results with HeLa plasma
membrane and the culture media conditioned by
growth of HeLa cells where the response to
LY181984 was inhibition.
In this report, we document a response of the
NADH oxidase activity of HeLa cell plasma mem-
branes and of sera to redox environment where the
same preparations will respond predominantly to the
antitumor sulfonylurea either as stimulation of activ-
 .  .ity oxidized or as inhibition of activity reduced .
The ability of reducing or oxidizing conditions to
modulate the NADH oxidase activity correlate as
well with the ability of reducing or oxidizing condi-
tions to modulate the growth of HeLa cells in re-
sponse to the anticancer drug.
2. Materials and methods
2.1. Growth of cells
HeLa S cells were grown on Dulbecco’s Modified
 .  .  .Eagles Medium D-MEM Joklik modified Gibco
 . with glutamine 244 mgrl and phosphate 1.3 grl
.Na HPO and without CaCl plus 5% donor horse2 4 2
 .  .serum. Gentamicin sulfate 50 mgrl Sigma and
 .sodium bicarbonate 2 grl were added. Cells were
collected by centrifugation for 6 min at 3000 rpm.
 .Attached HeLa cells ATCC CCL2 , were grown
 .in 25 cm flasks in Minimal Essential Medium MEM
 .Gibco , pH 7.4, at 378C with 10% fetal calf serum
 .heat-inactivated , plus 50 mgrl gentamicin sulfate
 .Sigma .
2.2. Purification of plasma membranes from HeLa
cells
HeLa cells grown as suspension cultures were
collected by centrifugation for 6 min at 1500=g.
The cell pellets were resuspended in 0.2 mM EDTA
in 1 mM NaHCO in an approximate ratio of 1 ml3
per 108 cells and incubated on ice for 10–30 min to
swell the cells. Homogenization was with a Polytron
homogenizer for 40 sec at 10 000 rpm using a 10
ST-probe and 7 ml aliquots. Cell survival was deter-
mined by Eosin Y exclusion. To estimate breakage,
the cells were monitored by light microscopy before
and after homogenization. At least 90% cell breakage
without breakage of nuclei was achieved routinely.
The homogenates were centrifuged for 10 min at
175=g to remove unbroken cells and nuclei and the
supernatant was centrifuged a second time for 30 min
at 25 000=g to prepare a plasma membrane-en-
riched microsome fraction. The supernatant was dis-
carded and the pellets were resuspended in 0.2 M
potassium phosphate buffer in a ratio of approxi-
mately 1 ml per pellet from 5=108 cells. The resus-
pended membranes were then loaded onto the two-
phase system constituted on a weight basis as fol-
 .lows. The two-phase system contained 6.6% wrw
 .  .Dextran T-500 Pharmacia , 6.6% wrw poly-
 .ethylene glycol 3350 Fisher , and 0.2 M potassium
 . w xphosphate buffer pH 7.2 7 . The weight of the
system was brought to 14 g with distilled water.
( )D.J. Morre et al.rBiochimica et Biophysica Acta 1369 1998 185–192´ 187
 .Resuspended microsomes 2 g were added to the
two-phase system to a final weight of 16 g. The tubes
were inverted vigorously for 40 times in the cold
 .48C . The phases were separated by centrifugation at
 .750 rpm 150=g in a Sorvall HB 4 rotor for 5 min.
The upper phases were carefully withdrawn with a
Pasteur pipette, divided in half and transferred into
40 ml plastic centrifuge tubes and diluted with 1 mM
cold NaHCO and centrifuged at 33 300=g in a3
HB-4 rotor for 30 min. The purity of the plasma
membrane was determined to be )90% by electron
microscope morphometry. The yield was 20 mg
plasma membrane protein from 1010 cells.
2.3. Spectrophotometric assay
NADH oxidase activities of sera were determined
as the disappearance of NADH measured at 340 nm
with 430 nm reference using an SLM Aminco DW-
2000 spectrophotometer in the dual wavelength mode
of operation with continuous recording over 5 min
intervals once steady-state rates were attained. The
reaction mixture contained 50 mM Tris–Mes buffer
 .pH 7.0 , 2 mM KCN to inhibit any potential mito-
chondrial oxidase activity, and 150 mM NADH in a
total volume of 2.5 ml. Assay was at 378C with
constant stirring.
For HeLa cell plasma membranes, the spectropho-
tometric assay was the same except that the reaction
was monitored by the decrease in absorbance at
340 nm using a Hitachi Model U3210 spectrophotom-
eter. Changes in absorbance were recorded as a func-
tion of time by a chart recorder with both instru-
ments. A millimolar extinction coefficient of
6.22 cmy1 was used to determine NADH disappear-
ance.
Proteins were determined by the bicinchoninic acid
 . w xBCA assay 8 using bovine serum albumin as
standard.
2.4. Growth measurement
Attached HeLa cells were treated in 35=10 mm
w xplastic dishes in 2.5 ml culture medium 9 . Sulfony-
lurea was dissolved in DMSO and added in 2.5 ml of
DMSO to yield a final DMSO concentration of 0.1%.
Controls received 2.5 ml of DMSO. Growth was de-
termined from cell numbers estimated by counting
the number of cells over defined areas consisting of a
grid of 1 mm squares after 24, 48 and 72 h of treat-
ment and by means of a hemocytometer after 96 h of
treatment. To release cells for counting, cells were
trypsinized with 0.05% Sigma 1 X trypsin containing
0.53 mM EDTA for 1 min.
3. Results
HeLa cell plasma membrane vesicles exhibited a
rate of NADH oxidation of about 1 nmolesrminrmg
protein. The activity normally was inhibited by
w xLY181984 with an LC of about 30 nM 3 . NADH50
oxidation was proportional to time and protein con-
centration. The K for NADH oxidation was aboutm
w x25mM 3 .
The rate of NADH oxidation in the absence of
sulfonylurea was only slightly altered by redox condi-
 .tions Fig. 1 . With reducing conditions provided by
 .1 mM dithiothrietol DTT , the activity was inhibited
 .by LY181984 with an EC of about 30 nM Fig. 1 .50
However, in the presence of oxidizing conditions,
Fig. 1. NADH oxidase activity of isolated vesicles of plasma
membranes from HeLa cells as a function of the concentration of
the antitumor sulfonylurea, LY181984, in the presence of either
1 mM dithiothreitol or 0.003% hydrogen peroxide. Results are
averages from 3 different plasma membrane preparations "
standard deviations.
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Fig. 2. NADH oxidase activity of isolated vesicles of plasma membranes from HeLa cells as a function of the concentration of LY181984
 .  .  .  .in the presence of either 100 mM reduced GSH or oxidized glutathione GSSG . A Freshly frozen plasma membranes. B Plasma
membranes stored frozen for 6 months. Results are averages from 4 different plasma membrane preparations " standard deviations.
i.e., 0.003% hydrogen peroxide, the LY181984 no
longer was inhibitory. Rather, stimulations were ob-
 .served Fig. 1 .
When the response to varying concentrations of
LY181984 was measured in the presence of either
 .  .reduced GSH or oxidized GSSG glutathione, inhi-
bition by LY181984 was enhanced with GSH. With
GSSG, not only did the LY181984 fail to inhibit
NADH oxidation, but a slight stimulation was ob-
  ..served Fig. 2 A . When assayed with preparations
 .of lower starting specific activity stored longer , the
degree of inhibition with GSH also was less Fig.
 ..2 B . However, GSSG under these conditions stimu-
lated activity over the entire range of GSSG concen-
trations tested.
In contrast to HeLa plasma membranes, the shed
form of the drug-responsive NADH oxidase was
either stimulated or inhibited by LY181984 depend-
Table 1
 .  . Response of NADH oxidase of patient sera ySU and response to 1 mM LY181984 in DMSO qSU comparing oxidizing 0.003%
.  .H 0 or reducing 1 mM DTT conditions. Units are NADH oxidase, nmolesrml serum2 2
Cancer Designation No Addition 0.003% H O 1 mM DTT2 2
ySU qSU Ratio ySU qSU Ratio ySU qSU Ratio
Breast SB-6 1.1 0.55 0.5 0.6 0.7 1.17 0.2 0.12 0.6
SB-21 0.22 0.35 1.6 0.9 1.2 1.33 0.55 0.4 0.55
SB-22 0.3 0.2 0.7 1.3 1.2 0.92 0.7 0.6 0.8
SB-104 0.45 0.35 0.8 1.5 1.7 1.13 0.6 0.5 0.8
Prostate SB-4 0.4 0.9 2.25 0.8 1.0 1.25 0.6 0.4 0.7
Ovarian SB-33 0.5 0.35 0.7 0.6 0.65 1.08 0.35 0.15 0.4
 .Leukemia CLL SB-29 0.5 0.3 0.6 0.45 1.0 2.22 0.2 0.1 0.5
Pancreatic SB-9 0.5 0.8 1.6 0.68 0.83 1.22 0.65 0.55 0.85
Bladder SB-69 0.4 0.35 0.9 0.35 0.5 1.43 0.3 0.1 0.3
Lung SB-5 0.4 0.2 0.5 0.9 1.1 1.22 0.5 0.25 0.5
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Table 2
 .  .Summary of NADH oxidase activity of patient sera ySU , response to 1 mM LY181984 in DMSO qSU and modulation by oxidizing
or reducing conditions. Units of specific activity are NADH oxidase, nmolesrml serum
Cancer Number of Redox ySU qSU Ratio 0.5–0.85 0.9–0.95 1.0 1.05–1.1 1.15–2.0
Patients Addition
Breast 8 No addition 0.66"0.2 0.62"0.2 0.94"0.3 4 0 1 0 3
8 0.003% H O 0.85"0.4 0.99"0.4 1.197"0.06 0 1 0 0 72 2
7 1 mM DTT 0.81"0.53 0.63"0.38 6.71"0.29 6 0 0 0 1
Leukemia 9 No addition 0.39"0.15 0.40"0.1 1.06"0.45 4 1 0 0 4
qLymphoma 9 0.003% H O 0.58"0.3 0.65"0.3 1.26"0.5 2 0 0 0 72 2
6 1 mM DTT 0.68"0.5 0.4"0.3 0.6"0.2 6 0 0 0 0
Lung 5 No addition 0.6"0.2 0.6"0.2 0.94"0.3 3 0 0 0 2
5 0.003% H O 0.9"0.3 1.07"0.3 1.19"0.06 0 0 0 0 52 2
5 1 mM DTT 0.5"0.1 0.25"0.05 0.6"0.02 4 0 0 0 1
Colon 5 No addition 0.6"0.2 0.5"0.1 0.95"0.2 3 0 0 0 2
5 0.003% H O 0.6"0.2 0.8"0.2 1.26"0.13 0 0 0 0 52 2
5 1 mM DTT 0.5"0.2 0.35"0.15 0.7"0.1 5 0 0 0 0
 w x.ing on the particular sample Table 1, Ref. 6 . Of
201 serum samples examined previously, 55% were
inhibited by sulfonylurea either LY181984 or
.LY217447 and 44% were stimulated by sulfonylurea
 .LY181984 .
To determine if the serum form also responded to
redox, sera were tested in the presence of 0.003%
 .hydrogen peroxide or 1 mM DTT Table 1 . In gen-
eral, initial rates were somewhat greater with hydro-
gen peroxide than with DTT. However, a most marked
change in the response to sulfonylurea was seen with
redox environment. For the 27 samples of cancer
patient sera of Table 2, the initial response to 1 mM
LY181984 was a nearly equal mixture of stimulations
and inhibitions. However, with 0.003% hydrogen
peroxide, the dominant response to 1 mM LY181984
was stimulation whereas with 1 mM DTT the domi-
nant response to LY181984 was inhibition.
The differences were not absolute however. Of the
four breast cancer sera of Table 1, one was not
stimulated by 1 mM LY181984 in the presence of
0.003% hydrogen peroxide. With the data summa-
rized in Table 2, of the 27 samples of sera from
cancer patients, 1 mM LY181984 inhibited in 15 of
the samples and stimulated with 11 in the absence of
any additions. With 0.003% hydrogen peroxide, 1 mM
LY181984 stimulated in 24 of the 27 sera tested and
with 1 mM DTT, 1 mM LY181984 inhibited with 21
of the 23 samples tested. The same set of serum
samples was represented in each of the different
series so that there was a clear shift away from a
random distribution of stimulations and inhibitions by
1 mM LY181984 to inhibition under reducing condi-
tions and stimulation under oxidizing conditions. The
one specimen of sera from a breast cancer patient
neither inhibited nor stimulated by LY181984 with
no addition was stimulated by LY181984 qSUry
.SU ratio of 1.28 in the presence of 0.003% hydrogen
peroxide. Results with 0.003% and 0.03% hydrogen
peroxide were equivalent.
Table 3
 .NADH oxidase activity of sera from healthy laboratory volunteers ySU and response to 1 mM antitumor sulfonylurea, LY181984 in
 .DMSO qSU comparing different redox conditions during assay
Redox Condition N NADH oxidase nmolesrml serum Ratio, qSUrySU
ySU qSU
No Addition 25 0.38"0.08 0.38"0.08 1.0"0.02
0.003% H O 23 0.78"0.29 0.77"0.28 0.98"0.062 2
0.03% H O 10 0.74"0.21 0.74"0.21 1.0"0.012 2
1 mM DTT 15 0.6"0.3 0.6"0.3 1.0"0.03
10 mM DTT 4 0.3"0.1 0.3"0.1 1.0"0.05
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Fig. 3. Growth of HeLa cells after 96 h as a function of the
concentration of LY181984. The solid circles are with no addi-
tion. The open triangles are with 1mM GSSG and the solid
triangles are with 1mM GSH. These concentrations of GSH and
GSSG were selected to be within the range of concentrations not
affecting the growth of HeLa cells in the absence of LY181984.
Values are from three determinations " standard deviations.
Fig. 4. NADH oxidase activity of plasma membrane vesicles
isolated from HeLa cells and assayed in the presence of varying
concentrations of LY181984 in the presence of 100 mM L-cy-
steine.
Fig. 5. Growth of HeLa cells after 96 h as a function of sulfony-
lurea concentration in the presence or absence of 100 mM L-cys-
teine.
With sera from healthy volunteers, the hydrogen
peroxide appeared to stimulate activity although the
 .increase was not highly significant Table 3 . How-
ever, none of the oxidizing or reducing conditions
resulted in a response, either stimulation or inhibi-
tion, to 1 mM of the sulfonylurea LY181984 of more
 .than "6% Table 3 .
Not only did the redox environment affect the
response of the NADH oxidase to LY181984, it also
altered the growth response of HeLa cells to
LY181984. Reduced glutathione at a concentration of
1mM increased the efficacy of LY181984 by about
one log order in magnitude compared to no addition
 .Fig. 3 . With 1 mM GSSG, the efficacy of LY181984
in growth inhibition was decreased by at least one log
 .order compared to no addition Fig. 3 .
The inhibition of NADH oxidation by LY181984
 .was enhanced by cysteine Fig. 4 . When cysteine
was added to the culture medium, the ability of
LY181984 to kill HeLa cells also was enhanced Fig.
.5 .
4. Discussion
The activity of cell surface NADH oxidase corre-
w xlates with the growth rate of HeLa cells 6 . When
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w xinhibited, as with capsaicin 10 or by the antitumor
w xsulfonylurea 11 , or with submicromolar concentra-
w xtions of retinoic acid 12 , the cells appear to undergo
apoptotic cell death as evidenced by an increase in
w xDAPI fluorescence 10,11 and DNA fragmentation
w x  .12 . At much higher concentrations e.g. 100 mM ,
capsaicin and retinoic acid also slowed growth and
w xinduced apoptosis in non-transformed cells 9,10 .
w xWolvetang et al. 13 demonstrated that the NADH
oxidase-mediated apoptosis was blocked by antisera
to the cell surface oxidase and could be reversed by
addition of coenzyme Q. The response of transformed
cells to these apoptosis-inducing agents is much more
specific than with nontransformed cells. Inhibitions
occurred with transformed cells in the submicromolar
and nanomolar range. These concentrations have no
effect either on the NADH oxidase or on growth or
w xsurvival of non-transformed cells 10 .
The drug-responsive NADH oxidase is assumed to
be widely distributed among different tumor types.
This supposition is based on the observation that a
sulfonylurea-responsive NADH oxidase is present in
sera of patients with late-stage cancer representing a
variety of solid tumors, leukemias and lymphomas
w x6 . The activity has also been demonstrated directly
with a small number of human tumors and trans-
formed cell lines HeLa, MCF10A mammary adeno-
carcinoma, HL-60 leukemia, colon xenografts,
. w xglioblastoma . Sera from normal volunteers 6 and
w xnontransformed cells and tissues 14 appeared to
lack the activity.
A major anomaly encountered with the sera sam-
ples was that, while the majority did respond to
sulfonylurea, the responses were nearly equally di-
w xvided among inhibition and stimulation 6 . The vari-
ations were reproducible and not correlated with tu-
mor type, gender, age, conditions of sera collection
or storage or geographic distribution or therapy. The
possibility that the response might be related to the
oxidation or reduction state of the oxidase was first
raised with binding experiments where binding of
radiolabeled LY181984 to isolated plasma membrane
vesicles of HeLa was enhanced in the presence of
reduced glutathione or dithiothreitol and reduced with
w xhydrogen peroxide 2 .
When effects of similar treatments were evaluated
with NADH oxidase activities of HeLa cell plasma
membranes, a very marked effect on the sulfonylurea
response was observed. As with sulfonylurea binding,
if the membranes were in a reducing environment
and sulfonylurea binding affinity was enhanced, so
was the degree of inhibition of activity enhanced.
This response was seen also with sera of cancer
patients where, with no addition, approximately half
responded to LY181984 by inhibition of activity. The
majority of the remainder were stimulated. However,
in the presence of DTT, LY181984 resulted in inhibi-
tion in )90% of the serum samples including sam-
ples where, in the absence of DTT, the LY181984
resulted in a stimulation of activity. In an oxidizing
environment, the NADH oxidase activity of the
plasma membrane vesicles was stimulated.
w xActivity responses of enzymatic activities 15 and
w xreceptor function 16,17 to redox conditions are not
without precedent. The usual interpretation involves
some dependence on the breakage or formation of
w xdisulfide bonds 15 . With the effect on the NADH
oxidase, the response of the membrane-associated
forms would appear to be the result of a direct effect
on the protein itself since an altered response to drug
was seen as well with the shed form of the activity in
sera of cancer patients.
An unexpected outcome of an explanation based
on affinity of drug binding was the stimulation of
NADH oxidation in response to LY181984 under
oxidizing conditions imposed by GSSG or dilute
hydrogen peroxide. While it may be that oxidizing
conditions in serum, for example, favor a stimulatory
drug response, other factors also may be involved
since the response of serum samples to the redox
environment was not absolute. What seems to occur
and was seen also with the data for HeLa cells of Fig.
2, was that oxidation tended to reduce inhibition
whereas reduction tended to enhance inhibition
against some background level of drug response that
may also influence degree of drug inhibition or stim-
ulation of the enzymatic activity, i.e., different activ-
ity forms.
The response to oxidizing and reducing conditions
does not appear to be that of a cosubstrate. For
example, with the response to dithiothreitol, there
was no clear dose dependency. The response was
approximately the same at 1, 10 and 100 mM. The
response to hydrogen peroxide was similar with
0.0003, 0.003 and 0.03%. Also results with dithio-
threitol, reduced glutathione and cysteine were equiv-
( )D.J. Morre et al.rBiochimica et Biophysica Acta 1369 1998 185–192´192
alent as were results with oxidized glutathione and
hydrogen peroxide. A direct effect on the drug was
ruled out for dithiothrietol and glutathione, both oxi-
 .dized and reduced, using the radiolabeled drug 1, 2 .
Despite the possibility of yet unappreciated levels
of complexity, the redox state of the NADH oxidase
appears to have relevance in terms of the growth
response of HeLa cells to the sulfonylurea. The en-
hancement of inhibition of the oxidase and enhanced
w xbinding to plasma membranes 1,2 is reflected in an
enhanced inhibition of growth under reducing condi-
tions achieved either with reduced glutathione or
dithiothreitol. With the oxidizing conditions afforded
by oxidized glutathione, the sulfonylurea was nearly
without effect on the growth of cells. These findings
suggest the possibility of therapeutic benefit from
modifying the redox environment of anticancer drugs
which may target the cell surface NADH oxidase. A
response to oxidation or reduction was observed with
mouse melanoma and the vanilloid, capsaicin 8-
.methyl-N-vanillyl-6-noneamide , both in vitro and in
w xvivo with tumors transplanted subcutaneously 18 .
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